{"passport":{"unfragile":{"@version":"1.0","version":"2026-05","artifact":{"id":"tool_drugcard","slug":"drugcard","name":"DrugCard","type":"product","url":"https://drug-card.io","page_url":"https://unfragile.ai/drugcard","categories":["data-analysis"],"tags":[],"pricing":{"model":"paid","free":false,"starting_price":null},"status":"active","verified":false},"capabilities":[{"id":"tool_drugcard__cap_0","uri":"capability://data.processing.analysis.multi.language.adverse.event.report.processing.and.normalization","name":"multi-language adverse event report processing and normalization","description":"Processes adverse event reports submitted in multiple languages (estimated 10+ supported based on 'multi-language' positioning) and normalizes them into standardized pharmacovigilance data structures (MedDRA coding, severity classification, causality assessment). Uses NLP pipelines with language detection and domain-specific entity extraction to map free-text clinical narratives into structured safety signals, enabling downstream regulatory compliance workflows without manual translation or data entry.","intents":["Process adverse event reports from global clinical sites without manual translation bottlenecks","Automatically extract and code adverse events using MedDRA terminology across language barriers","Reduce time-to-signal detection by normalizing multilingual unstructured safety data into queryable structured formats"],"best_for":["Global pharmaceutical companies managing Phase III/IV trials across 10+ countries","Contract Research Organizations (CROs) handling multicenter studies with diverse patient populations","Mid-sized pharma lacking dedicated multilingual pharmacovigilance teams"],"limitations":["No public validation against FDA/EMA MedDRA coding accuracy standards — critical for regulatory submissions","Language support scope unknown; likely excludes rare languages or regional dialects used in emerging markets","Causality assessment algorithms not disclosed — may not meet ICH E2A causality categories required for regulatory reporting","Dependent on input data quality; garbage-in-garbage-out for poorly structured or incomplete adverse event narratives"],"requires":["Adverse event reports in text format (free-text narratives, structured forms, or PDF)","Integration with existing pharmacovigilance database or EHR system for signal correlation","API credentials or data pipeline connection to DrugCard backend"],"input_types":["text (free-text adverse event narratives)","structured data (eCRF adverse event forms)","semi-structured (PDF case reports)"],"output_types":["structured data (MedDRA-coded adverse events with severity/causality)","JSON (standardized safety signal objects)","CSV/database records (for integration with pharmacovigilance databases)"],"categories":["data-processing-analysis","text-generation-language","healthcare-compliance"],"confidence":0.5,"matches":0,"success_rate":0},{"id":"tool_drugcard__cap_1","uri":"capability://text.generation.language.conversational.pharmacovigilance.query.interface.with.chatbot","name":"conversational pharmacovigilance query interface with chatbot","description":"Provides a natural language chatbot interface that allows non-technical pharmacovigilance staff (safety monitors, medical writers) to query adverse event databases, generate safety reports, and explore signal trends using conversational prompts rather than SQL or complex BI tools. The chatbot likely uses retrieval-augmented generation (RAG) to ground responses in the organization's adverse event data and regulatory guidance documents, with context management to maintain conversation state across multi-turn queries about specific drugs, populations, or safety signals.","intents":["Query adverse event databases using plain English instead of SQL or BI tool syntax","Generate ad-hoc safety reports and trend analyses without involving data analysts","Explore signal hypotheses conversationally (e.g., 'What adverse events are most common in elderly patients taking Drug X?')"],"best_for":["Pharmacovigilance teams with limited data science expertise","Organizations seeking to democratize access to safety data beyond specialized analysts","Regulatory affairs teams needing rapid ad-hoc reporting for FDA/EMA inquiries"],"limitations":["Chatbot accuracy depends on underlying data quality and RAG retrieval relevance — hallucinations possible if adverse event database is incomplete or inconsistent","No disclosed guardrails for regulatory compliance; risk of generating non-compliant safety narratives if chatbot is not constrained to approved terminology and formats","Conversation context management may not persist across sessions, limiting ability to build complex multi-step analyses","Unknown whether chatbot enforces role-based access control — critical for protecting patient privacy in adverse event data"],"requires":["Adverse event database or data warehouse with structured safety data","Integration with DrugCard backend via API or data pipeline","User authentication and role-based access control (RBAC) for regulatory compliance","Web browser or mobile app for chatbot interface"],"input_types":["text (natural language queries in English; multilingual support unknown)"],"output_types":["text (conversational responses with safety insights)","structured data (tables, charts, summary statistics)","documents (generated safety reports in PDF or Word format)"],"categories":["text-generation-language","memory-knowledge","planning-reasoning"],"confidence":0.5,"matches":0,"success_rate":0},{"id":"tool_drugcard__cap_2","uri":"capability://data.processing.analysis.signal.detection.and.adverse.event.trend.analysis","name":"signal detection and adverse event trend analysis","description":"Analyzes adverse event datasets to identify emerging safety signals and trends using statistical methods (disproportionality analysis, temporal clustering) and machine learning pattern recognition. The system likely compares observed adverse event frequencies against expected baseline rates, flags unusual clusters by patient demographics or drug combinations, and generates alerts for potential new safety issues. Integration with pharmacovigilance databases enables continuous monitoring and automated signal escalation workflows.","intents":["Detect emerging safety signals faster than manual review by identifying statistically unusual adverse event clusters","Monitor adverse event trends over time to identify population-specific risks (e.g., hepatotoxicity in elderly patients)","Prioritize adverse events for regulatory reporting based on signal strength and clinical relevance"],"best_for":["Pharmaceutical companies managing large adverse event databases (10,000+ reports)","Post-market surveillance teams seeking to automate signal detection workflows","Regulatory affairs teams needing objective, auditable signal identification for FDA/EMA submissions"],"limitations":["Signal detection algorithms not disclosed — unknown whether they meet FDA/EMA standards for disproportionality analysis (ROR, PRR, BCPNN)","Baseline rate assumptions may not account for confounding factors (e.g., indication bias, reporting bias) that skew signal detection","No disclosed validation against known safety signals or false positive rates","Temporal clustering detection may miss slow-onset adverse events or rare serious events with sparse data"],"requires":["Adverse event database with minimum sample size (likely 1,000+ reports for statistical significance)","Structured adverse event data with dates, drug names, adverse event terms, and patient demographics","Integration with DrugCard backend or data pipeline for continuous monitoring"],"input_types":["structured data (adverse event database records with dates, drug names, adverse event terms, demographics)"],"output_types":["structured data (signal alerts with statistical metrics: ROR, PRR, confidence intervals)","text (signal summaries and clinical narratives)","visualizations (trend charts, heatmaps of adverse event clusters)"],"categories":["data-processing-analysis","planning-reasoning","safety-moderation"],"confidence":0.5,"matches":0,"success_rate":0},{"id":"tool_drugcard__cap_3","uri":"capability://data.processing.analysis.regulatory.compliance.report.generation.with.audit.trail","name":"regulatory compliance report generation with audit trail","description":"Generates standardized pharmacovigilance reports (Periodic Safety Update Reports, Individual Case Safety Reports, Development Safety Update Reports) in formats required by FDA, EMA, and other regulatory bodies. The system likely maintains audit trails documenting data lineage, transformation steps, and user actions to support regulatory inspections. Integration with adverse event databases and signal detection workflows enables automated report population with current safety data, reducing manual compilation time and transcription errors.","intents":["Generate FDA/EMA-compliant safety reports without manual document assembly and formatting","Maintain audit trails for regulatory inspections demonstrating data integrity and compliance","Automate periodic safety report updates as new adverse event data becomes available"],"best_for":["Pharmaceutical companies with FDA/EMA product approvals requiring periodic safety reporting","Regulatory affairs teams managing multiple products with overlapping reporting deadlines","Organizations undergoing FDA/EMA inspections requiring documented data lineage and audit trails"],"limitations":["Report template compliance not validated against current FDA/EMA guidance — risk of non-compliant submissions if templates are outdated","Audit trail implementation details unknown; may not meet 21 CFR Part 11 or EMA GCP requirements for electronic records","No disclosed validation against regulatory reviewer expectations — generated reports may lack required narrative context or clinical interpretation","Dependent on upstream data quality; inaccurate adverse event coding or missing safety data will propagate into regulatory submissions"],"requires":["Adverse event database with complete safety data (adverse events, outcomes, dates, patient demographics)","Signal detection results and safety analysis summaries","Integration with DrugCard backend for automated report generation","Regulatory guidance documents (FDA, EMA) for template compliance"],"input_types":["structured data (adverse event database records, signal detection results, safety metrics)"],"output_types":["documents (PDF/Word regulatory reports: PSUR, ICSR, DSUR)","structured data (XML or eCopy format for regulatory submissions)","audit logs (data lineage and user action trails)"],"categories":["data-processing-analysis","automation-workflow","safety-moderation"],"confidence":0.5,"matches":0,"success_rate":0},{"id":"tool_drugcard__cap_4","uri":"capability://data.processing.analysis.adverse.event.data.integration.and.normalization.from.heterogeneous.sources","name":"adverse event data integration and normalization from heterogeneous sources","description":"Ingests adverse event data from multiple sources (EHRs, clinical trial management systems, patient registries, spontaneous reporting systems) with different data formats and schemas, then normalizes them into a unified pharmacovigilance data model. Uses data mapping, deduplication, and validation logic to reconcile conflicting information and ensure data consistency. Likely implements ETL pipelines with error handling and data quality checks to flag incomplete or inconsistent records before downstream processing.","intents":["Consolidate adverse event data from multiple clinical systems without manual data entry or reconciliation","Deduplicate adverse event reports from multiple sources to avoid double-counting in signal detection","Validate incoming adverse event data against regulatory standards (MedDRA, severity classifications) before analysis"],"best_for":["Pharmaceutical companies with multiple clinical trial sites or EHR systems","Organizations consolidating adverse event data from acquisitions or partnerships","CROs managing adverse event data from multiple sponsors with different reporting standards"],"limitations":["Data mapping logic not disclosed — unknown whether it handles all common EHR/CTMS formats or requires custom integration per system","Deduplication algorithm accuracy unknown; risk of missing duplicate reports if matching logic is too strict or too loose","Data quality validation rules not disclosed; may not catch all inconsistencies or missing required fields","No disclosed handling of data privacy/de-identification — risk of exposing patient identifiers during integration"],"requires":["Access to source systems (EHRs, CTMS, registries) with appropriate data extraction permissions","API connections or data export capabilities from source systems","Data mapping specifications or configuration for each source system","Integration with DrugCard backend for data ingestion and normalization"],"input_types":["structured data (EHR adverse event records, CTMS case reports, registry data)","semi-structured data (CSV/Excel adverse event exports)","unstructured data (PDF case reports, clinical notes)"],"output_types":["structured data (normalized adverse event records in unified pharmacovigilance schema)","data quality reports (validation errors, missing fields, duplicate flags)"],"categories":["data-processing-analysis","tool-use-integration","automation-workflow"],"confidence":0.5,"matches":0,"success_rate":0},{"id":"tool_drugcard__cap_5","uri":"capability://data.processing.analysis.patient.population.stratification.and.subgroup.adverse.event.analysis","name":"patient population stratification and subgroup adverse event analysis","description":"Analyzes adverse event patterns across patient subgroups defined by demographics (age, gender, ethnicity), comorbidities, concomitant medications, or genetic markers. Uses statistical methods (stratified analysis, interaction testing) to identify population-specific safety signals and risk factors. Enables identification of vulnerable populations (e.g., elderly, renal impairment) with elevated adverse event risk, supporting targeted safety monitoring and labeling updates.","intents":["Identify adverse events that disproportionately affect specific patient populations (elderly, renal impairment, etc.)","Detect drug-drug interactions or contraindications by analyzing adverse events in patients on concomitant medications","Support label updates and risk minimization strategies by quantifying population-specific safety risks"],"best_for":["Pharmaceutical companies managing drugs with known population-specific risks (e.g., geriatric, renal impairment)","Regulatory affairs teams preparing label updates or Risk Evaluation and Mitigation Strategies (REMS)","Post-market surveillance teams monitoring safety in vulnerable populations"],"limitations":["Stratification variables depend on data availability; missing demographic or comorbidity data limits subgroup analysis depth","Statistical power for subgroup analysis may be insufficient for rare adverse events or small subpopulations","No disclosed handling of confounding factors (e.g., indication bias, severity of illness) that may skew subgroup comparisons","Genetic stratification (pharmacogenomics) likely not supported without explicit genetic testing data integration"],"requires":["Adverse event database with complete patient demographic and clinical data (age, gender, comorbidities, concomitant medications)","Minimum sample size per subgroup for statistical significance (likely 30-50+ events per stratum)","Integration with DrugCard backend for subgroup analysis workflows"],"input_types":["structured data (adverse event records with patient demographics, comorbidities, concomitant medications)"],"output_types":["structured data (subgroup-stratified adverse event frequencies, odds ratios, confidence intervals)","visualizations (forest plots, stratification heatmaps)","text (subgroup safety summaries and clinical interpretations)"],"categories":["data-processing-analysis","planning-reasoning"],"confidence":0.5,"matches":0,"success_rate":0},{"id":"tool_drugcard__cap_6","uri":"capability://automation.workflow.real.time.adverse.event.monitoring.and.alert.escalation","name":"real-time adverse event monitoring and alert escalation","description":"Monitors incoming adverse event reports in real-time and automatically escalates high-priority safety signals to designated pharmacovigilance staff based on configurable alert rules (e.g., serious adverse events, unexpected events, signal threshold breaches). Uses event streaming or polling mechanisms to detect new reports and trigger workflows (email notifications, task creation, escalation to medical review). Enables rapid response to emerging safety issues without manual daily report review.","intents":["Detect serious or unexpected adverse events immediately upon report submission without waiting for manual review cycles","Automatically escalate high-priority safety signals to appropriate staff based on event severity and clinical relevance","Reduce time-to-response for emerging safety issues by triggering automated workflows"],"best_for":["Pharmaceutical companies managing large adverse event volumes requiring rapid response","Post-market surveillance teams monitoring safety in real-time across multiple products","Organizations with regulatory requirements for rapid serious adverse event reporting (24-48 hour timelines)"],"limitations":["Alert rule configuration not disclosed; may require manual tuning to balance sensitivity (catch all signals) vs. specificity (avoid alert fatigue)","Real-time monitoring latency unknown; may not meet 24-hour serious adverse event reporting timelines if processing delays occur","No disclosed integration with external notification systems (email, SMS, Slack) — may require custom integration","Alert fatigue risk if thresholds are too sensitive; may lead to alert desensitization and missed critical signals"],"requires":["Adverse event data source with real-time or near-real-time data availability (streaming API or polling mechanism)","Configurable alert rules and escalation workflows","Integration with notification systems (email, SMS, task management tools)","Integration with DrugCard backend for real-time monitoring"],"input_types":["structured data (incoming adverse event reports in real-time)"],"output_types":["alerts (email, SMS, in-app notifications)","structured data (escalation tasks, alert logs)"],"categories":["automation-workflow","safety-moderation","planning-reasoning"],"confidence":0.5,"matches":0,"success_rate":0},{"id":"tool_drugcard__cap_7","uri":"capability://data.processing.analysis.drug.drug.interaction.and.contraindication.detection.in.adverse.event.context","name":"drug-drug interaction and contraindication detection in adverse event context","description":"Analyzes adverse events in patients taking multiple concomitant medications to identify potential drug-drug interactions or contraindications. Cross-references adverse event patterns against known drug interaction databases and clinical guidelines to flag unexpected interactions or contraindicated combinations. Enables identification of safety signals arising from medication combinations rather than individual drugs, supporting label updates and clinical guidance.","intents":["Identify adverse events potentially caused by drug-drug interactions in patients on concomitant medications","Detect contraindicated drug combinations based on adverse event patterns and clinical guidelines","Support label updates and clinical guidance by quantifying interaction-related safety risks"],"best_for":["Pharmaceutical companies managing drugs with known interaction risks","Regulatory affairs teams preparing label updates for drug-drug interactions","Post-market surveillance teams monitoring safety in polypharmacy populations"],"limitations":["Drug interaction detection depends on completeness of concomitant medication data; missing medication information limits analysis","Interaction database coverage unknown; may not include all known interactions or emerging interactions from recent literature","Causality attribution difficult for interaction-related adverse events; unclear whether adverse event is due to primary drug, concomitant drug, or interaction","No disclosed integration with clinical guidelines or contraindication databases"],"requires":["Adverse event database with complete concomitant medication data","Drug interaction database or clinical guideline integration","Integration with DrugCard backend for interaction analysis"],"input_types":["structured data (adverse event records with concomitant medication lists)"],"output_types":["structured data (interaction-related adverse event frequencies, interaction alerts)","text (interaction safety summaries and clinical interpretations)"],"categories":["data-processing-analysis","safety-moderation"],"confidence":0.5,"matches":0,"success_rate":0}],"trust":{"score":40,"verified":false,"data_access_risk":"high","permissions":["Adverse event reports in text format (free-text narratives, structured forms, or PDF)","Integration with existing pharmacovigilance database or EHR system for signal correlation","API credentials or data pipeline connection to DrugCard backend","Adverse event database or data warehouse with structured safety data","Integration with DrugCard backend via API or data pipeline","User authentication and role-based access control (RBAC) for regulatory compliance","Web browser or mobile app for chatbot interface","Adverse event database with minimum sample size (likely 1,000+ reports for statistical significance)","Structured adverse event data with dates, drug names, adverse event terms, and patient demographics","Integration with DrugCard backend or data pipeline for continuous monitoring"],"failure_modes":["No public validation against FDA/EMA MedDRA coding accuracy standards — critical for regulatory submissions","Language support scope unknown; likely excludes rare languages or regional dialects used in emerging markets","Causality assessment algorithms not disclosed — may not meet ICH E2A causality categories required for regulatory reporting","Dependent on input data quality; garbage-in-garbage-out for poorly structured or incomplete adverse event narratives","Chatbot accuracy depends on underlying data quality and RAG retrieval relevance — hallucinations possible if adverse event database is incomplete or inconsistent","No disclosed guardrails for regulatory compliance; risk of generating non-compliant safety narratives if chatbot is not constrained to approved terminology and formats","Conversation context management may not persist across sessions, limiting ability to build complex multi-step analyses","Unknown whether chatbot enforces role-based access control — critical for protecting patient privacy in adverse event data","Signal detection algorithms not disclosed — unknown whether they meet FDA/EMA standards for disproportionality analysis (ROR, PRR, BCPNN)","Baseline rate assumptions may not account for confounding factors (e.g., indication bias, reporting bias) that skew signal detection","builder identity is not verified yet","no observed match outcomes yet"],"rank_breakdown":{"adoption":0.31666666666666665,"quality":0.67,"ecosystem":0.25,"match_graph":0.25,"freshness":0.75,"weights":{"adoption":0.25,"quality":0.25,"ecosystem":0.1,"match_graph":0.35,"freshness":0.05}},"observed_outcomes":{"matches":0,"success_rate":0,"avg_confidence":0,"top_intents":[],"last_matched_at":null},"maintenance":{"status":"active","updated_at":"2026-05-24T12:16:30.283Z","last_scraped_at":"2026-04-05T13:23:42.561Z","last_commit":null},"community":{"stars":null,"forks":null,"weekly_downloads":null,"model_downloads":null,"model_likes":null}},"distribution":{"claim_url":"https://unfragile.ai/submit?claim=drugcard","compare_url":"https://unfragile.ai/compare?artifact=drugcard"}},"signature":"LnK+0rA8WED4l54x0CzV1wJoM3b1NJKkweJ44+WwLQhBE4Rsc9H5qyFRSKZyjIqAc82ugc2cD8zR3zGZARVNAQ==","signedAt":"2026-06-21T15:44:41.178Z","signedBy":"unfragile.ai","version":1},"_links":{"self":"https://unfragile.ai/api/v1/passport/drugcard","artifact":"https://unfragile.ai/drugcard","verify":"https://unfragile.ai/api/v1/verify?slug=drugcard","publicKey":"https://unfragile.ai/api/v1/trust-passport-public-key","spec":"https://unfragile.ai/trust","schema":"https://unfragile.ai/schema.json","docs":"https://unfragile.ai/docs"}}